A role of Cyclosporine A that suppresses multi-drug resistance (MDR) in the secondary chemotherapy drug resistant cell line of ovarian cancer.
- Author:
Chun San AN
1
;
Sung Yob KIM
;
Chul Min PARK
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Cheju National University, Jeju, Korea. obgymd@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Ovarian cancer;
Multi-drug resistance;
MDR1/P-gp;
Cyclosporine A
- MeSH:
Blotting, Western;
Cell Line*;
Cisplatin;
Cyclosporine*;
Drug Resistance, Multiple*;
Drug Therapy*;
Genes, MDR;
Humans;
Ovarian Neoplasms*;
Paclitaxel;
Recurrence
- From:Korean Journal of Gynecologic Oncology
2006;17(4):286-293
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Resistant, recurrent ovarian cancer patients who had first chemotherapy with Cisplatin have showed low reactivity and high recurrence in the secondary chemotherapy. Therefore, multi-drug resistance (MDR) to chemotherapy is a major obstacle in attempts to improve the clinical outcome of ovarian cancer patients. The aim of our study is to analyze the sensitivity of some chemotherapy drugs when we co-use Cyclosporine A (CsA), which suppresses MDR, in the secondary drug resistant cell line. METHODS: After establishing the secondary drug resistant cell line, drug sensitivity was measured by MTT assay. MDR gene and protein were analyzed by RT-PCR and western blotting assay. RESULTS: MDR gene (MDR1) and protein (P-gp) were overexpressed in the secondary drug resistant cell line. When we measured the sensitivity of some chemotherapy drug after using the amounts of CsA that can suppress MDR1/P-gp, the sensitivity of Paclitaxel was highest. CONCLUSION: CsA has a role that makes the sensitivity of chemotherapy drug higher in the secondary drug resistant cell line by suppression of multi-drug resistance. Therefore, we could expect that the proper use of MDR suppresser like CsA with secondary chemotherapy drug would help to cure resistant, recurrent ovarian cancer patients.
